Skip to main content
SpringerLink
Log in

Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review

  • Research Letter
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Booth CM, Detsky AS. Why patients receive treatments that are minimally effective? Nat Rev Clin Oncol. 2019;16(1):3–4.

    Article  Google Scholar 

  2. Prasad V, McCabe C, Mailankody S. Low-value approvals and high prices might incentivize ineffective drug development. Nat Rev Clin Oncol. 2018;15(7):399–400.

    Article  Google Scholar 

  3. Hilal T, Gonzalez-Velez M, Prasad V. Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration. JAMA Intern Med. 2020;180(8):1108–15.

    Article  CAS  Google Scholar 

  4. Andersen SK, Penner N, Chambers A, Trudeau ME, Chan KKW, Cheung MC. Conditional approval of cancer drugs in Canada: accountability and impact on public funding. Curr Oncol. 2019;26(1):e100–5.

    Article  CAS  Google Scholar 

  5. Raymakers AJN, Regier DA, Peacock SJ. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review. Cancer. 2020;126(1):148–55.

    Article  Google Scholar 

  6. Streiner DL, Norman GR. Drug trial phases. Community Oncol. 2009;6(1):36–40.

    Article  Google Scholar 

  7. Pontes C, Zara C, Torrent-Farnell J, Obach M, Nadal C, Vella-Bonanno P, et al. Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. Appl Health Econ Health Policy [Internet]. 2019 Nov 7. https://doi.org/10.1007/s40258-019-00527-x (cited 2019 Nov 20).

  8. pCODR Expert Review Committee (pERC) Final Recommendation: Lartruvo for Advanced Soft Tissue Sarcoma. [Internet]. Canadian Agency for Drugs and Technologies in Health, pan-Canadian Oncology Drug Review. 2018. https://www.cadth.ca/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_fn_rec.pdf.

  9. Srikanthan A, Penner N, Chan KKW, Sabharwal M, Grill A. Understanding the reasons for provincial discordance in cancer drug funding—a survey of policymakers. Curr Oncol. 2018;25(4):257–61. https://doi.org/10.3747/co.25.3993.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO® [Internet]. Eli Lilly and Company. 2019. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-results-phase-3-soft-tissue-sarcoma-study (cited 2019 Dec 13).

  11. Lartruvo (Olaratumab) for Advanced Soft Tissue Sarcoma (pCODR 10111) [Internet]. Canadian Agency for Drugs and Technologies in Health, pan-Canadian Oncology Drug Review. 2019. https://www.cadth.ca/sites/default/files/pcodr/pcodr_profund_olaratumab_lartruvo_sts.pdf (cited 2019 Dec 13).

  12. Arrowsmith J. Phase III and submission failures: 2007–2010. Nat Rev Drug Discov. 2011;10(2):87–87.

    Article  CAS  Google Scholar 

  13. Garrison LP, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, et al. Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16(5):703–19.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada

    Adam J. N. Raymakers, Dean A. Regier & Stuart J. Peacock

  2. Cancer Control Research, BC Cancer, Vancouver, BC, Canada

    Adam J. N. Raymakers, Dean A. Regier & Stuart J. Peacock

  3. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada

    Adam J. N. Raymakers & Stuart J. Peacock

  4. School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada

    Kristina M. Jenei & Dean A. Regier

  5. School of Population and Public Health, W. Maurice Young Centre for Applied Ethics, University of British Columbia, Provost’s Office, Kelowna, BC, Canada

    Michael M. Burgess

Authors
  1. Adam J. N. Raymakers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kristina M. Jenei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dean A. Regier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael M. Burgess
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stuart J. Peacock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam J. N. Raymakers.

Ethics declarations

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflict of Interest

Adam Raymakers is supported by a Michael Smith Foundation for Health Research Research Trainee Award and has served as an economics guidance panel lead for the pan-Canadian Oncology Drug Review (2014–2016). Kristina Jenei is supported by a Canadian Institute of Health Research (CIHR) Masters Award (CGS-M). Dean Regier has received funding for conference travel from Illumina and honoraria from Roche. Stuart Peacock has served in a role on the Canadian Agency for Drugs and Technologies in Health Board of Directors as the Academic Member.

Availability of Data and Material

Not applicable

Ethics Approval

Not applicable.

Informed Consent

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raymakers, A.J.N., Jenei, K.M., Regier, D.A. et al. Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review. PharmacoEconomics 39, 373–377 (2021). https://doi.org/10.1007/s40273-020-00995-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-020-00995-3

Search

Navigation